Steroid-Refractory cGvHD: Emerging Treatment Options
April 12th 2024This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Watch
Diagnosis and Initial Management of cGVHD
April 12th 2024This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion covers factors that guide the decision-making process, such as organ involvement, severity of symptoms, and response to initial therapy.
Watch
Evaluating Patient-Reported Outcomes in MAGNITUDE Trial for mCRPC
April 4th 2024Kim N. Chi, MD, FRCPC, discusses the significance of the phase 3 MAGNITUDE trial, including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer.
Watch
Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
April 3rd 2024Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.
Watch